HOME > MARKETS > COMPANY NEWS
  COMPANY NEWS
COMPANY
Caplin Point’s arm gets USFDA’s final nod for Potassium Phosphates Injection
Mar-13-2026

Caplin Point Laboratories’ subsidiary -- Caplin Steriles (CSL) has received final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Potassium Phosphates Injection USP, (phosphorus 3 mmol/mL and potassium 4.4 mEq/mL in 5 mL, 15 mL and 50 mL Vials), a generic therapeutic equivalent version of the Reference Listed Drug (RLD) from Fresenius Kabi USA, LLC (NDA 212832).

Potassium Phosphates Injection is used as a source of phosphorus in intravenous fluids to correct hypophosphatemia and as parenteral nutrition in adults and pediatric patients, who cannot take oral supplements. According to IQVIATM (IMS Health), Potassium Phosphates injection USP, (phosphorus 3 mmol/mL and potassium 4.4 mEq/mL in 5 mL, 15 mL and 50 mL Vials) had US sales of around $57 million for the 12-month period ending January 2026.

Caplin Point Laboratories is the mid-sized company in India’s pharmaceutical sector to be engaged in the manufacture of APIs, finished formulations, research & development, clinical research, frontend generic presence in Latin America, brand marketing in Francophone Africa and an USFDA approved injectable facility.

  RELATED NEWS >>